Theriva Biologics, Inc. (TOVX) Stock Price & Analysis
Theriva Biologics, Inc. (TOVX) — MoonshotScore 20/100 (Weak band), calculated Nov 18, 2026. Price $0.12 (-6.25%), as of the Nov 20, 2026 trading session; market cap $5.51M.
Educational signal · not a buy or sell recommendation · How to read this
Theriva Biologics, Inc. · TOVX · AMEX
Theriva Biologics Inc. is a clinical-stage biotechnology company focused on developing therapeutics for diseases with high unmet needs.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Theriva Biologics (TOVX)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality, a fragile balance sheet and an expensive valuation. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Strained; Valuation: Bubble; Growth Durability: Growing; Momentum: Slipping.
Earnings yield is the main valuation drag relative to sector peers.
- quarterly revenue $300,000 (Q1 FY2026, quarter ended Mar 31, 2026)
- EPS beat 3 of the last 8 reports
- Altman Z -16.86 · Piotroski F 3
Holding back: weak fundamentals, balance-sheet strain, a rich price, weak price trend
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 19 | Weak | |
| 20 | Weak | |
| 20 | Weak | |
| 20 | Weak | |
| 20 | Weak | |
| 20 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.12 | |
| Change on the day | -6.25% | |
| Market capitalisation | $5.51M | — |
| Shares traded on the day | 1.24M |
Price & events
Other perspectives
Council score for Theriva Biologics (TOVX): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
3 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 31, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Theriva Biologics (TOVX), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Theriva Biologics, Inc. (TOVX) is listed on AMEX. It employs 15 people. In Q1 FY2026 it reported revenue of $300,000 and net income of -$2M. The market values it at $5.51M.
What do the latest results show for Theriva Biologics (TOVX)?
Short answer · as of
The most recent reported quarter, Q1 FY2026, carried revenue of $300,000. Against analyst estimates the company has EPS beat 3 of the last 8 reports.
Quarterly income statement — 1 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 FY2026 | $300,000 | -$2M | -$0.05 (diluted) |
What are the financial strengths and risks for Theriva Biologics (TOVX)?
Short answer · as of
What is holding it back is weak fundamentals, balance-sheet strain, a rich price, weak price trend. The distress and quality screens read Altman Z -16.86 · Piotroski F 3. Trailing ratios: ROE -65.0% · ROA -27.7% · current ratio 1.21 · earnings yield -132.0%.
Data-derived red flags
- Listing risk — at $0.12 the shares sit below the $1.00 minimum bid AMEX requires for continued listing.
- Financial-distress signal — its Altman Z-Score of -16.86 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-65.0%) — the business is not currently generating profit on shareholder capital.
How does Theriva Biologics compare with its peers?
Short answer
Theriva Biologics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.45 Nov 19, 2026 | $475M | 91 5-pillar Nov 18, 2026 | |
| $8.76 Nov 20, 2026 | $521M | 91 5-pillar Nov 18, 2026 | |
| $2.90 Nov 20, 2026 | $245M | 90 5-pillar Nov 18, 2026 | |
| $40.09 Nov 20, 2026 | $755M | 88 5-pillar Nov 18, 2026 | |
| $15.47 Nov 20, 2026 | $86.6M | 82 5-pillar Nov 18, 2026 | |
| $10.92 Nov 20, 2026 | $99.3M | 82 5-pillar Nov 18, 2026 | |
| $3.69 Nov 19, 2026 | $160M | 72 5-pillar Nov 18, 2026 | |
| $1.84 Nov 20, 2026 | $174M | 69 5-pillar Nov 18, 2026 | |
| $9.19 Nov 20, 2026 | $540M | 68 5-pillar Nov 18, 2026 | |
| $7.98 Nov 20, 2026 | $780M | 63 5-pillar Nov 18, 2026 | |
| $10.02 Nov 20, 2026 | $148M | 61 5-pillar Nov 18, 2026 | |
| $6.11 Nov 20, 2026 | $488M | 60 5-pillar Nov 18, 2026 | |
| Theriva Biologics (TOVX) — this page | $0.12 | $5.51M | 20 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Insider activity
Form 4 records via FMP · Most recent available transactions
- Transactions
- 12
- Identified insiders
- 4
- Purchases
- 0
- Sales
- 0
- Other transactions
- 12
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held TOVX in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported TOVX in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Theriva Biologics (TOVX)?
Theriva Biologics Stock: Key Questions Answered
These answers are editorial: 1 of these 9 answers is drawn from the TOVX research dossier (written May 4, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for TOVX?
TOVX carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is TOVX a good stock to buy?
Stock Expert AI does not rate TOVX buy, sell or hold. Theriva Biologics, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the TOVX stock price today?
The last price recorded for Theriva Biologics, Inc. (TOVX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
How does Theriva Biologics, Inc. plan to fund its operations?
As a clinical-stage biotechnology company, Theriva Biologics, Inc. primarily relies on external funding to support its operations. The company has historically raised capital through equity offerings, debt financing, and strategic collaborations. Future funding needs will depend on the progress of its clinical trials and the expansion of its product pipeline.
What are the key factors to evaluate for TOVX?
Theriva Biologics, Inc. (TOVX) holds a MoonshotScore in the low range. Continued cultivation of strategic alliances will be crucial for long-term success. Not financial advice.
How frequently does TOVX data refresh on this page?
TOVX's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven TOVX's recent stock price performance?
Theriva Biologics, Inc. (TOVX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on high unmet medical needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TOVX overvalued or undervalued right now?
Theriva Biologics, Inc. (TOVX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research TOVX before investing?
Before investing in Theriva Biologics, Inc. (TOVX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 4, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 15 figures on this page — 9 from Financial Modeling Prep (FMP), 4 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com